What are the criteria for continuing, adjusting, or discontinuing either therapy
Exenatide Protects against glucose- and lipid-induced endothelial dysfunction: evidence for direct vasodilation effect of GLP-1 receptor agonists in humans
The dose-findings studies reported here not only documented the superior efficacy of GLP1/E in the management of metabolic alterations in our obese PCOS model, including lowering body weight and adiposity, as well as improvement of glucose handling and insulin resistance, but also highlighted a non-monotonic effect of this dual agonist in PNA mice, with optimal effects being achieved with submaximal doses
Among American adults who have taken these medications, 62% said they used them both to treat a chronic condition such as diabetes or heart disease and to lose weight, including 39% who said they used the medications only to treat a chronic condition
Detailed body composition data shows lean mass losses of approximately 6.5 kg occurred alongside fat mass reductions exceeding 10 kg with higher doses
Researchers continue investigating which receptor combinations produce optimal outcomes for different patient populations
